Eosinophils in Asthma-closing the loop or opening the door?

New England Journal of Medicine

Volumn 360, Issue 10, 2009, Pages 1026-1028

  Wenzel, Sally E ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; INTERLEUKIN 5 ANTIBODY; MEPOLIZUMAB; INTERLEUKIN 5; MONOCLONAL ANTIBODY;

AIRWAY OBSTRUCTION; ASTHMA; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; EOSINOPHILIA; HUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; DRUG ANTAGONISM; EOSINOPHIL; FORCED EXPIRATORY VOLUME; IMMUNOLOGY; LEUKOCYTE COUNT; NOTE; PHYSIOLOGY;

ANTIBODIES, MONOCLONAL; ASTHMA; EOSINOPHILIA; EOSINOPHILS; FORCED EXPIRATORY VOLUME; HUMANS; INTERLEUKIN-5; LEUKOCYTE COUNT;

EID: 61849152860     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe0900334     Document Type: Editorial

References (12)

1. Nair P, Pizzichini MMM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-93.
2. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-84.
3. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleu-kin-5 blocking monoclonal antibody on eosinophils, airway hy-per-responsiveness, and the late asthmatic response. Lancet 2000 356:2144-8.
4. Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007;176:1062-71.
5. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160:1001-8.
6. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178:218-24.
7. Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004;113:101-8.
8. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715-21.
9. Simpson JL, Scott RJ, Boyle MJ, Gibson PG. Differential proteolytic enzyme activity in eosinophilic and neutrophilic asthma. Am J Respir Crit Care Med 2005;172:559-65.
10. Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006;27:483-94.
11. Plötz S-G, Simon H-U, Darsow U, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003;349:2334-9.
12. Garrett JK, Jameson SC, Thomson B, et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 2004;113:115-9.